Shares of Ocugen Inc. OCGN climbed 12.13% to $0.71 Tuesday, on what proved to be an all-around positive trading session for ...

US-based biotechnology company Ocugen has received approval from the Data and Safety Monitoring Board (DSMB) to begin dosing ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

March 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported fourth quarter ...

March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...

Ocugen reported clinical trial progress and financial results, highlighting advancements in gene therapies for retinal diseases and recent FDA alignments. OCU410ST is a therapy for Stargardt ...

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

Shares of Ocugen Inc. OCGN rose 5.43% to $0.64 Monday, on what proved to be an all-around great trading session for the stock ...

Ocugen’s biologic candidate moved into the clinic and patients are currently being dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). OCU200 has the potential to change ...

Ocugen ( NASDAQ:OCGN ) Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from FY... MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the ...

Ocugen ( NASDAQ:OCGN ) Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from FY... MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the ...